

PAR/CS/NSE/2022-23/54

To,

The Manager

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G,

Bandra Kurla Complex, Bandra (E),

Mumbai- 400 051

Maharashtra

Date: 21/01/2023

Subject: INSPECTION FOR RENEWAL OF WHO-GMP CERTIFICATION

Ref.: **Symbol - PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

With reference to above captioned subject, we would like to inform that based on an e-mail received on Friday, 20th January, 2023 at 7:38 PM from OFFICE OF THE DEPUTY DRUG CONTROLLER (INDIA), our company being WHO-GMP Certified, it will undergone for inspection on **January 23, 2023 & January 24, 2023** at manufacturing premises and sites located at 333/1, GIDC Industrial Estate, Phase-II, Chitra, Bhavnagar - 364004, Gujarat, India by officers of Central Drugs Standard Control Organization (CDSCO) and Food And Drugs Control Administration (FDCA) to ensure the pharmaceutical products are consistently produced and controlled according to quality standard and to determine the degree of compliance according to guidelines along with good laboratory practices and good clinical practices.

The above visit shall fall under ordinary course of business of the Company and will not involving any Unpublished Price sensitive Information during the aforesaid visit.

You are requested to kindly take note on your record.

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Sanket B. Trivedi)**Company Secretary & Compliance Officer**